Indomethacin Enhances Brown Fat Activity

Area of Science:

• Metabolism and Endocrinology
• Pharmacology

Background:

• Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), is known to induce white adipocyte differentiation.
• The effects of indomethacin on brown adipocyte differentiation, activation, and its role in obesity remain largely unknown.

Purpose of the Study:

• To investigate the role of indomethacin in brown adipocyte differentiation and activation.
• To determine the effects of indomethacin on brown adipose tissue (BAT) and obesity in mice.

Main Methods:

• Treatment of mouse brown preadipocytes with varying doses of indomethacin.
• Delivery of indomethacin to the interscapular brown adipose tissue (iBAT) of diet-induced obese (DIO) mice via osmotic pumps.
• Analysis of adipocyte differentiation markers, UCP1 and PPARγ coactivator 1-alpha expression, PPAR response element activation, iBAT mass, blood glucose levels, and histological changes.

Main Results:

• Indomethacin dose-dependently increased brown preadipocyte differentiation and upregulated UCP1 and PPARγ coactivator 1-alpha.
• Indomethacin activated the PPAR response element, suggesting it acts as a PPARγ agonist.
• In DIO mice, indomethacin reduced iBAT mass, fasting blood glucose, and mitigated diet-induced whitening of BAT by promoting smaller lipid droplets and increasing UCP1 mRNA expression.

Conclusions:

• Indomethacin promotes brown adipocyte differentiation in vitro.
• Indomethacin may enhance brown fat function and glucose oxidation capacity in diet-induced obesity.
• These findings suggest a potential therapeutic role for indomethacin in managing obesity and related metabolic disorders.